Payment overview · 2025
General Payments
$758.41
41 reported records · 12 companies
Healthcare provider profile · identity verified
Zhexiang Li, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FLORHAM PARK, NJ · NPI 1710929898
Verified facts
What the public records show
CMS Open Payments records show Zhexiang Li, MD received $758.41 in general payments during 2025 across 41 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 27.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Farxiga, Jardiance, Mounjaro, Ozempic, Shingrix.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $205.72 | 27.1% | 11 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $79.88 | 10.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $74.41 | 9.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $70.82 | 9.3% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $68.52 | 9.0% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $63.35 | 8.3% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $55.28 | 7.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.36 | 6.5% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $34.31 | 4.5% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.76 | 2.7% | 1 | 2025 |
| Rhythm Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.46 | 2.6% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.54 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $758.41 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $205.72 | 11 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $70.82 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $68.52 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $63.35 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $55.59 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $55.35 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $55.28 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $49.36 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $49.36 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $49.36 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $34.31 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.48 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $24.29 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.76 | 1 | 2025 |
Source payment records
|
|||||
| IMCIVREE Normalized: imcivree |
Drug | Rhythm Pharmaceuticals, Inc. | $19.46 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $16.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 55 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 71 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 63 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
71 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
63 | 40 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
71 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
55 | 55 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
104 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 416 | 95 |
| Amlodipine Besylate | Amlodipine Besylate | 312 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 305 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 301 | 51 |
| Valsartan | Valsartan | 259 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 254 | 65 |
| Escitalopram Oxalate | Escitalopram Oxalate | 202 | 25 |
| Losartan Potassium | Losartan Potassium | 186 | 36 |
| Donepezil Hcl | Donepezil Hcl | 174 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 161 | 32 |
| Potassium Chloride | Potassium Chloride | 140 | 33 |
| Furosemide | Furosemide | 139 | 41 |
| Mirtazapine | Mirtazapine | 124 | 24 |
| Metformin Hcl Er | Metformin Hcl | 119 | 39 |
| Eliquis | Apixaban | 104 | 16 |
| Lisinopril | Lisinopril | 99 | 25 |
| Metformin Hcl | Metformin Hcl | 91 | 21 |
| Sertraline Hcl | Sertraline Hcl | 91 | 20 |
| Trazodone Hcl | Trazodone Hcl | 91 | 24 |
| Divalproex Sodium | Divalproex Sodium | 88 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 85 | 19 |
| Torsemide | Torsemide | 85 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 83 | 21 |
| Xarelto | Rivaroxaban | 83 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 22 |
| Gabapentin | Gabapentin | 80 | 20 |
| Famotidine | Famotidine | 76 | 16 |
| Montelukast Sodium | Montelukast Sodium | 75 | 14 |
| Memantine Hcl | Memantine Hcl | 74 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | 24 |
| Jardiance | Empagliflozin | 71 | 15 |
| Ezetimibe | Ezetimibe | 70 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 68 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 66 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 63 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 12 |
| Latanoprost | Latanoprost | 62 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 14 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 55 | 55 |
| Breo Ellipta | Fluticasone/Vilanterol | 52 | suppressed |
| Nystatin | Nystatin | 52 | 16 |
| Spironolactone | Spironolactone | 51 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 50 | 13 |
| Methenamine Hippurate | Methenamine Hippurate | 45 | suppressed |
| Simvastatin | Simvastatin | 41 | 11 |
| Buspirone Hcl | Buspirone Hcl | 39 | suppressed |
| Carvedilol | Carvedilol | 39 | suppressed |
| Myrbetriq | Mirabegron | 38 | suppressed |
| Ramipril | Ramipril | 36 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Ketoconazole | Ketoconazole | 33 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 32 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 30 | 22 |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Trimethoprim | Trimethoprim | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Omeprazole | Omeprazole | 28 | suppressed |
| Methimazole | Methimazole | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 25 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Timolol Maleate | Timolol Maleate | 20 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 19 | 19 |
| Atenolol | Atenolol | 19 | suppressed |
| Azithromycin | Azithromycin | 19 | 19 |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Allopurinol | Allopurinol | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Lumigan | Bimatoprost | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 14 |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Ozempic | Semaglutide | 17 | suppressed |
| Repaglinide | Repaglinide | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Perphenazine | Perphenazine | 11 | suppressed |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $758.41 · 41 records | Bayer Healthcare Pharmaceuticals Inc. | ABRYSVO, COMIRNATY, CONTRAVE, Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE 3, IMCIVREE, JARDIANCE, Kerendia, MOUNJARO, Ozempic, PREVNAR 20, REXULTI, SHINGRIX, The Cologuard Plus Collection Kit, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error